Everything below concerns ACTH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Moore supports a balance between securing the United States' borders and creating pathways to citizenship for those already in the country. In June 2023, Moore said that he supported efforts to strengthen the federal temporary protected status policy for immigrants living in the United States. In June 2024, after a man who had entered the United States illegally was arrested in connection with the murder of Rachel Morin, Moore blamed congressional inaction on the issue of immigration as well as conditions at the Mexico–United States border for Morin's killing. In June 2023, after multiple Republican governors sent members of their state national guards to the southern border, Moore told WRC-TV that he did not support sending members of the Maryland National Guard to the border. In January 2025, he declined to say if he would deploy Maryland National Guard members at the southern border if asked by the federal government. Moore also advised local jurisdictions to "follow the Constitution" when cooperating with federal immigration efforts. In May 2025, he signed into law the Maryland Values Act, which prohibits federal law enforcement from conducting immigration actions at sensitive locations. In April 2025, Moore condemned the Trump administration's deportation of Kilmar Abrego Garcia on the grounds of inadequate due process, saying that "no one should be deported to the very county where a judge determined they will face persecution" and calling on the federal government to "correct" their error.
===== UPMC Montefiore ===== UPMC Montefiore, part of UPMC Presbyterian, was founded as Montefiore Hospital in 1908 by the Ladies Hospital Aid Society as a hospital for Jewish physicians and patients. Montefiore Hospital affiliated with the University of Pittsburgh School of Medicine in 1957 and joined UPMC in 1990. It is the home to the clinical transplantation facilities originally headed by transplant pioneer Thomas Starzl and is physically connected to UPMC Presbyterian and UPMC Eye and Ear by a series of pedestrian bridges.
=== Pain === The weak opioid codeine, in low doses and combined with one or more other drugs, is available in prescription medicines and, in some jurisdictions, without a prescription to treat mild pain. Other opioids are usually reserved for the relief of moderate to severe pain.
For example, enteric coatings only dissolve in the basic environment of the intestines. Drugs held in solution do not need to be dissolved before being absorbed. Lipid-soluble drugs are absorbed more rapidly than water-soluble drugs.
Promising results of health and medical research are reported: mouse-tested novel antibiotics class (including Zosurabalpin) against A. baumannii (3 Jan), small-trialed focused ultrasound for blood–brain barrier opening for better medication (Aducanumab) entry against Alzheimer's disease (3 Jan), a review supports the efficacy of exercise against depression (15 Jan), an available blood test to detect Alzheimer's disease with high accuracy using p-tau217 (22 Jan), one of two small-trialed gene therapies against DFNB9-deafness (24 Jan), phase 3-trialed dengue vaccine effective against at least two of four dengue types (31 Jan) Hazard research is published: ~240.000 particles of microplastic and nanoplastics (~90%) per liter are found in samples of plastic-bottled water (8 Jan), a study estimates harmful chemicals used in plastic materials have caused $249 billion U.S. healthcare system costs in 2018 (11 Jan), a study indicates fungal infections may be causing millions more deaths annually than thought (12 Jan), a study of European plastic waste exports to Vietnam finds a large fraction is dumped in nature and suggests air pollution from melting plastics and untreated wastewater have significant impact on health (18 Jan).
Sources: en.wikipedia.org
N-Acetyl-γ-aminobutyric acid (N-acetyl-GABA), also known as N-acetyl-4-aminobutyric acid, is a metabolic intermediate in the biosynthesis of γ-aminobutyric acid (GABA) from putrescine. Other intermediates in this pathway include N-acetylputrescine and N-acetyl-γ-aminobutyraldehyde (N-acetyl-GABAL or N-acetyl-GABA aldehyde). Enzymes mediating the transformations in this pathway include putrescine acetyltransferase (PAT), monoamine oxidase B (MAO-B), aldehyde dehydrogenase (ALDH), and an unknown deacetylase enzyme. The pathway is a minor pathway in GABA synthesis compared to the main pathway in which GABA is synthesized from glutamate. However, the pathway has been found to have an important physiological role in the brain, for instance in the production of GABA in the striatum and resultant inhibition of dopaminergic neurons in this brain area.
CPA3 (also known as mast-cell CPA) is involved in the digestion of proteins by mast cells. CPA4 (previously known as CPA-3, but renumbered when mast-cell CPA was designated CPA-3) may be involved in tumor progression, but this enzyme has not been well studied. CPA5 has not been well studied. CPA6 is expressed in many tissues during mouse development, and in adult shows a more limited distribution in brain and several other tissues. CPA6 is present in the extracellular matrix where it is enzymatically active. A human mutation of CPA-6 has been linked to Duane's syndrome (abnormal eye movement). Recently, mutations in CPA6 were found to be linked to epilepsy. CPA6 is also one of several enzymes which degrade enkephalins.
Some forms of MODY produce significant hyperglycemia and the typical signs and symptoms of diabetes: increased thirst and urination (polydipsia and polyuria). In contrast, many people with MODY have no signs or symptoms and are diagnosed either by accident, when a high glucose is discovered during testing for other reasons, or screening of relatives of a person discovered to have diabetes. Discovery of mild hyperglycemia during a routine glucose tolerance test for pregnancy is particularly characteristic. While the goals of diabetes management are the same no matter what type, there are two primary advantages of confirming a diagnosis of MODY.
David W. Wood (born in 1967) is an American chemical engineer who is professor of chemical and biomolecular engineering at Ohio State University. Wood is also associated with the Department of Chemistry and Biochemistry and Molecular Biophysics Training Program. Wood is best known for his work on self-removing affinity tag methods, which he first published in Nature Biotechnology while a Ph.D. student at Rensselaer Polytechnic Institute. This method was also patented as a part of a collaboration with co-inventors at the Wadsworth Center of the New York State Department of Health and Rensselaer Polytechnic Institute, including Marlene Belfort, Georges Belfort, Victoria Derbyshire, and Wei Wu.
Sources: en.wikipedia.org
== External links == Proprotein+Convertase+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P63239 (Mouse Neuroendocrine convertase 1) at the PDBe-KB.
Endoxifen, also known as 4-hydroxy-N-desmethyltamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group as well as a protein kinase C (PKC) inhibitor. It is under development for the treatment of estrogen receptor-positive breast cancer and for the treatment of mania in bipolar disorder. It is taken by mouth. Endoxifen is an active metabolite of tamoxifen and has been found to be effective in patients that have failed previous hormonal therapies (tamoxifen, aromatase inhibitors, and fulvestrant). The prodrug tamoxifen is metabolized by the CYP2D6 enzyme to produce endoxifen and afimoxifene (4-hydroxytamoxifen). Currently, endoxifen is approved by Drugs Controller General of India for the acute treatment of manic episode with or without mixed features of Bipolar I disorder. It is manufactured and sold by Intas Pharmaceuticals under the brand name Zonalta.
== History == When methyldopa was first introduced, it was the mainstay of antihypertensive treatment, but its use has declined on account of relatively severe adverse side effects, with increased use of other safer and more tolerable agents such as alpha blockers, beta blockers, and calcium channel blockers. Additionally, it has yet to be associated with reducing adverse cardiovascular events including myocardial infarction and stroke, or overall all-cause mortality reduction in clinical trials. Nonetheless, one of methyldopa's still current indications is in the management of pregnancy-induced hypertension (PIH), as it is relatively safe in pregnancy compared to many other antihypertensives which may affect the fetus.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.